Lindsay Androski is the President and Chief Executive Officer of Arbutus Biopharma Corporation, a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapeutics with a focus on delivering novel lipid nanoparticle (LNP) delivery technology for liver-targeted treatments. She assumed the role of President and CEO in May 2023, after serving as the company's Chief Financial Officer since 2018. Under her leadership, Arbutus has advanced its pipeline, including key programs like AB-729, an RNAi therapeutic for chronic hepatitis B virus (HBV) infection, and AB-101 for metabolic dysfunction-associated steatohepatitis (MASH), while strengthening its proprietary LNP platform to enable extrhepatic delivery applications. Androski brings over two decades of financial and operational leadership experience in the biotechnology sector. Prior to Arbutus, she was Vice President of Finance at Zymeworks Inc., where she oversaw financial planning, investor relations, and business development during the company's growth phase. Her earlier roles include senior finance positions at Sophiris Bio, Oncothyreon, and as a senior manager at Ernst & Young, where she honed her expertise in public company accounting and strategic finance. A Chartered Professional Accountant (CPA, CA), Androski holds a Bachelor of Commerce degree from the University of British Columbia. Her tenure at Arbutus has been marked by significant achievements, including securing substantial financing through equity offerings and partnerships, optimizing operational efficiency, and progressing clinical programs toward key milestones. Androski's strategic vision positions Arbutus to leverage its LNP technology for broader therapeutic applications, driving value for shareholders and advancing transformative treatments for unmet medical needs in liver diseases.